BW
CERO

Boaz Weinstein’s CERo Therapeutics CERO Stock Holding History

Boaz Weinstein’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-606
Closed -$12.4M – 808
2022
Q4 		$12.4M Hold
606
– – 0.17% 202
2022
Q3 		$12.2M Buy
606
+40
+7% +$806K 0.14% 268
2022
Q2 		$11.3M Buy
566
+199
+54% +$3.99M 0.13% 266
2022
Q1 		$7.34M Buy
367
+47
+15% +$935K 0.1% 338
2021
Q4 		$6.34M Buy
+320
New +$6.35M 0.1% 307

Other funds holding CERO

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.1B AUM 13.6% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Boaz Weinstein's CERO Position: Q1 2023 in Review

Boaz Weinstein sold out of CERo Therapeutics (CERO) in Q1 2023, closing a stake of 606 shares — an estimated $12.4M sold.

Boaz Weinstein first reported a position in CERO in Q4 2021 and held it in 5 quarters. The position peaked at $12.4M in Q4 2022. 15 funds tracked by Wall St. Rank hold CERO as of Q1 2023.

  • Boaz Weinstein reported no remaining CERo Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Boaz Weinstein sold 606 CERo Therapeutics shares in Q1 2023, an estimated $12.4M.
  • Boaz Weinstein first reported a position in CERo Therapeutics in Q4 2021 and held it in 5 quarters.
  • Boaz Weinstein's CERo Therapeutics position peaked at $12.4M in Q4 2022.
  • 15 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2023.

Based on Saba Capital Management's 13F filing for Q1 2023, filed 15 May 2023.